Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mentor's synthetic pelvic prolapse mesh:

This article was originally published in Clinica

Executive Summary

Mentor has received US FDA 510(k) clearance to sell its first synthetic mesh product for treating pelvic organ prolapse, NovaSilk. The use of synthetic meshes for the treatment of pelvic organ prolapse represents one of the fastest growing segments of the women's health market, claimed the Santa Barbara, California firm, which already sells two human tissue-based products for the condition. NovaSilk comprises a macroporous, knitted, monofilament polypropylene mesh, while also being soft and light. It offers resistance to traction, allows tissue colonisation and facilitates positioning during surgery, the company said. According to Mentor, pelvic organ prolapse is estimated to afflict around 36 million women in the US and Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel